• No results found

Strategies for optimal suppression of rheumatoid arthritis Kooij, S.M. van der

N/A
N/A
Protected

Academic year: 2021

Share "Strategies for optimal suppression of rheumatoid arthritis Kooij, S.M. van der"

Copied!
15
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Strategies for optimal suppression of rheumatoid arthritis

Kooij, S.M. van der

Citation

Kooij, S. M. van der. (2009, January 22). Strategies for optimal suppression of rheumatoid arthritis. Retrieved from https://hdl.handle.net/1887/13425

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the

University of Leiden

Downloaded from: https://hdl.handle.net/1887/13425

Note: To cite this publication please use the final published version (if

applicable).

(2)



(3)

  ,A>NF:MHB=

,A>NF:MHB=

:??><ML :??><ML IHINE:MBHG

;NK=>G O>EHI F>MKB<

I:BG EHG@

PAB<A A:O>

=>LMKN<MBHG MA>

"BLMHKR

.A>

/-

LD>E>MHGL

<HGLBLM>GM G:M>=

>GMBMR L<KB;>=

=>L<KBIMBHG

!>G>K:E

(4)



B:@GHLBL

><:NL>

FBFB<

<KBM>KB:

F>KB<:G MA>F K>IHKML K>LNEML HK F:MHB=

:G=

IK>L>GM

.A>

<:NL>

BG IK>L>G<>

MKB;NM>L

<KBM>KB:

<>GMER

?>K>GMB:M>=

.K>:MF>GM

.K>:MF>GM K:M>

MA>

LH?M

=KN@L B<L L>O>K>

:<B=

HIF>GM LRGMA>LBS>=

PHKE=PB=>

=:M>

>KG NLN:EER

GMBKA>NF:MB<

MA>

',L

:@>

=B??>K>GM

<NKK>GM

(5)

 

!HE=

,

MH LBG<>

-NE?:L:E:SBG>

P:L

?:NEMR 5 7

<HF;BG:MBHG

<:<R

#G :;E>

<HKMB<HLM>KHB=L HGLMK:M>=

.A>

O>KLR LRLM>FB<

',L

KHF PBMA

<:NL>

F:MB<

.A>

MA>

H?

MABHIKBG>

HIKBG>

>?–<:<R

.A>

>?–<:<R

<R<EHLIHKBG>

HMK>Q:M>

#G 5 7 ENLMK:M>=

HMA>K MNK:E F@ P>>D :M>

@:BGLM BG

&>—NGHFB=>

BG

>?–<:<R

(6)



.(

?:<MHK CHBGM A>K:E=>=

@:M>=



BG—BQBF:;

BFIK>LLBO>ER BG@ ≤

57

;>G>–M BG—BQBF:;

PBMA

)MA>K ANF:G BS>=

<EBGB<:E BG HMK>Q:M>

MK>:MF>GM MK:=BMBHG:E KBHK

=:F:@>

PBMA I:MB>GML HMK>Q:M>

IK>LLBO>

;R 5 7 .A>

:II>:KL BG@

MBHGL

?KHF H?

HMA>K :M

<HNGMKB>L MH M>G :

(>P

:;HNM

(7)

 

PBMABG :GMB;H=B>L

<HGMBGNHNL

#G

=KN@L

@KHNI IKH<>LL :;:M:<>IM MK>:MF>GM .H<BEBSNF:;

MA>L>

MA>

.K>:MF>GM

NKBG@

:<AB>O>=

/GMBE

IRK:FB=

LN<A CHBGM

FBE=>LM

LN:E

KHNG=

L:PMHHMA

K><H@GBS>=

?NG<MBHG:E :II>:K>=

<HGMBGN>=

;>BG@

:G=

IKH@K>LLBHG

.A>

:IIKH:<A



=:F:@>

 :G

 :=CNLMF>GML

KHNMBG>

.A>L>

FBLLBHG

BG—:FF:MBHG

(8)



A:IM>K MB>GML IN;EBLA>=

EBGB<:E

.A>

;R MKB:EL :<MBOBMR .A>

#G=>Q P>EE;>BG@

:G=

?HEEHPBG@

-

.H NLBG@

H?≤  LAHPG MBHGL



<HGMBGN:MBHG

?HK<>

BL MK>:MF>GM

.H G:BK>

+N>LMBHGG:BK>

<HGMBGNHNL

<HGLB=>K>=

MH

.A>

BGLMKNF>GM BG<EN=>L Table 1. European League Against Rheumatism response criteria based on the disease activity score (DAS).

DAS at endpoint Improvement 1.2 Improvement ≤1.2 and 0.6 Improvement ≤0.6

≤ 2.4 Good response Moderate response No response

 2.4 and ≤ 3.7 Moderate response Moderate response No response

3.7 Moderate response No response No response

(9)

 

F>GML :K>

MA>

?NG<MBHG:E

,

MA>

MBHGBG@

-AHKM E:M>=



*-

L>KO>=

,:=BH@K:IAB<

->O>K:E :=:RL

">BC=>

MH CHBGM

">BC=>

=>O>EHI BL MA>

L<HK>

=:F:@>

<:G L<HK>

I:MB>GML

-

=N>

BG

>KHLBHGL

#G=BOB=N:EBS>=

,>LIHGL>L

>Q:FIE>

:M>

HMK>Q:M>

K>LIHGL>

MB–>=

?HK

@>G>MB<L K>LIHGL>

BG—N>G<>

(10)



.A>

1BMA MBHG .H

?KHF LM>IL GRF

;R ,>L>:K<A BG@

LM>INI MA>K:IR



MB>GML JN>GM

>O>KR ≤ 

<:E<NE:M>=

MA>

MA>K:IR

≤  : R>:KER :G=

NKBG@

IR

>:KEB>K I:MB>GML :<AB>O>



LMKBOBG@

?HEEHPNI

>@R ≤  HNM

=KBO>G K:=BHEH@B<:E K:=BH@K:IAB<

MH

I:MB>GML

M:I>K

LBHG

LBHG

MK>:MF>GM

:L

(11)

 

)NMEBG>

.ABL K><>GM K>FBLLBHG M:GM

 

<:E MBHG:E

>-M MA>

=BOB=N:E

=B??>K>GM

=B??>K>GM BG JN:EBMR L>GM>=

LBHG B >

?:BEBG@

:KMAKBMBL

MABL

(12)



 E>G<>

HEE>@>

-=EAF

 JN:EBMR :G=

 MBHGLABI

?NG<MBHG:E MBL

 HNM<HF>

PBMA MBL

 

 :G=

MHB=

 MHB=



<HF>

R>:KL

 K>FBLLBHG :KMAKBMBL

 LBO>

E:;:F:



=BL>:L>



=>

IKBFBMBO>



:KMAKBMBL





KA>NF:MB<



,A>NF:MBLF LB–<:MBHG





KA>NF:MHB=





NMH:GMB;H=B>L IKH@K>LLBHG NG=B??>K>GMB:M>=

JL@JALAK



KB:

AK



IK>=B<MBHG HGL>M MK>:MF>GM



BG

 L:EML



;L9



KA>NF:MHB=



KA>NF:MHB=



KA>NF:MHB=

MKB:E



<HFI:KBLHG HMK>Q:M>

>:KER



BLHG

>:KER MKB:E



F:MHB=

:G=

F>=B<:MBHGL



MHB=

F>MAHMK>Q:M>

MAK>>

=HN;E>;EBG=

 



:IR MA:G MBL

?KHF

FF

 MA>K:IR

<HGMKHEE>=

IA:L:E:SBG>

<HFIHG>GML



LNEIA:L:E:SBG>

IHG>GML MKHEE>=





:=K>G:E IHNG=

KA>NF:MHB=



HB=L E9LGD



<HB=L

G;@J9F=



>M :<MBO>

?RBG@

;EBG=

 



<HGMKHEE>=

>:L>

,@=ME



KA>NF:MHB=



?HK

 



'>MAHMK>Q:M>

KA>NF:MHB=

=HN;E>;EBG=

 MHB=





<R<EHLIHKBG :KMAKBMBL



PBMA :KMAKBMBL -MN=R



=HL>





LHG MK>:MF>GM MKB:E

,>?>K>G<>L

(13)

 



=>I>G=>GM :GMBKA>NF:MB<

MBHG:E



F>GM I:MB>GML

=KN@L



:<MBG@

R>:K

$



F:MHB=

:G=

#GO>LMB@:MHKL



*,'#,

;EBG=

FNF:;

:=:EBFNF:;

F:MHB=

MK>:MF>GM

 MB<

:M>

KA>NF:MHB=

E>=



E>—NGHFB=>

:KMAKBMBL HFBS>=

'=<



MBHG F:MHB=

,@=ME



=KN@

PH



MBHGL

?HK<>

MBHG:E

FF



E>—NGHFB=>

:<MBO>

FNEMB<>GMK>

&9F;=L



KA>NF:MHB=

B>L





F:;

:KMAKBMBL

KMAKBMBL '=<



K:=BH@K:IAB<

BFF>=B:M>

HG@HBG@

>:KER



>?–<:<R F:MHB=

,@=ME9LGD



HFI:KBLHG

<HF;BG>=

R>:K LMN=R

 



O>KLNL

:KMAKBMBL

JL@JALAK



<EBGB<:E F:;

;H=R

<HG<HFBM:GM

<HGMKHEE>=



G><M MK>:MF>GM MA>

:G=



;>G>–M :M>

BFIKHO>F>GM

MNFHK

<HG<HFBM:GM

 



LBHGL LMN=B>L

KHLBHGL



??><MBO>G>LL H?

MNFHK





;H=R HNL F>M::G:ERLBL MKHEE>=



?HEEHPBG@

I:MB>GML IK>MBG@

 



MNFHK

;:<M>KB:E :KMAKBMBL

 :KMAKBMBL /-



:GMBKA>NF:MB<

BOBO



EBGB<:E :=:EBFNF:;

<>GMK:MBHGL





EBQBF:;

I:MB>GML





F:;

<HF>





MHK ,@=ME



F>GM



F:MHB=

 



F:MB<

H?

,@=ME



HMA>K:IR

(14)



K:=BH@K:IAB<

–KLM

 M>KF LBHG ,@=ME



F>GM

<HFI:KBLHG F>GM



K>?>KK:E :GMBKA>NF:MB<

:KMAKBMBL



:IR KA>NF:MHB=



LMK:M>@R .#),

MKB:E



MK>:MF>GM MBL

BG LMK:M>@R



HIF>GM

<EBGB<:E

 



F>GM ,A>NF:MBLF

HFI:KBLHG ,A>NF:MHEH@R G:MBHG:E ,@=ME



:

F>KB<:G

<KBM>KB:

LGD



LBHG

<:E K>FBLLBHG

 HNM<HF>



F>GM

DAF



=B??>K>G<>

I:MB>GML



MHKL BG





:E :E@HKBMAF

=:F:@>

JL@JALAK



BG

 



'., BG=BOB=N:EBS>=

BFIKHO>F>GM KA>NF:MHB=



'., MHB=

MBL



 



MA>

 

 A>:EMA L>E><MBHG

  ':GN:E

#FKLALML=

 

=:MBHG - 

IHINE:MBHGL

  -A:KI O:G

  MA>

HEH@B<

JL@JALAK

  F:MHB=

  IKH@K>LLBHG I:MB>GML

,@=ME

  K>LIHGL>

KA>NF:MHB=

,A>NF:MHEH@R

 

  :EEHIKHM>BG:L>L I:MB>GML F:;

  G><KHLBL I>NMB<

:KMAKBMBL

)P>GJ<



<:<R :KMAKBMBL IABLFL LAK



@>G>MB<

H?

KA>NF:MHB=



>M MK>:MF>GM :KMAKBMBL

JL@JALAK



>M F:MHB=

 



/L>

:KMAKBMBL :G=



M>KF LMN=R



KA>NF:MHB=

F>MAHMK>Q:M>





IE:<>;H<HGMKHEE>=

KA>NF:MHB=

(15)

 

Referenties

GERELATEERDE DOCUMENTEN

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the. University

Significance between variables was tested by Student t test for normally distributed continuous variables; Mann-Whitney U test for non-nor- mally distributed variables; χ 2 test

Improvement throughout 2 years in functional ability (MACTAR), health related quality of life (physical and mental component summary scales of the SF-36), and VAS measurements

Cumulative probability distribu- tion of total Sharp-van der Heijde Score over 4 years of treatment with sequential monotherapy, step-up combination ther- apy, initial

Radiographic progression greater than the smallest detectable change SDC after 3 years, and IFX discontinuation 2 years after the start of MTX + IFX in the initial and delayed MTX +

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the. University

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the. University

Alle onderzoeksverpleegkundigen die hebben meegewerkt aan de BeSt studie in de verschillende ziekenhuizen, voor het uitvoeren van de gewrichtsscores en het samen met de